AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22845710
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) pramipexole to extended-release (ER) pramipexole
Trial: 22845710
Drug: Extended-release (ER)
RxNorm normalized name: Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release (ER) pramipexole
Trial: 11426364
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (5 g)
Trial: 26453066
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin infusion controlling glycemia at 4.5‐7.2 mmol/l (Group A)
Trial: 26453066
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin administered in three doses controlling glycemia at 7.2‐10.0 mmol/l (Group B)
Trial: 26453066
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C) without disturbances in carbohydrate metabolism
Trial: 22314814
Drug: Subcutaneous allergen-specific
RxNorm normalized name: Pacific halibut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous allergen-specific immunotherapy (SCIT)
Trial: 20389151
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand
Trial: 20389151
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks
Trial: 20389151
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand (meta-analysis)
Trial: 20389151
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg/12 h) and 2,000 ml water/24 h with tramadol on demand plus tamsulosin 0.4 mg/day over 3 weeks (meta-analysis)
Trial: 10187944
Drug: Combined steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 560 mg over 12 days)
Trial: 10187944
Drug: Combined steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined steroid therapy (nasal budesonide spray 2 x 0.1 mg/day and oral fluocortolone with a total dose of 715 mg over 20 days)
Trial: 10187944
Drug: Combined steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined steroid therapy
Trial: 7738344
Drug: Lugol's solution
RxNorm normalized name: Lugol's Solution
DrugBank: Potassium triiodide (DB14492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol's solution (approximately 170 ppm free molecular iodine)
Trial: 7738344
Drug: Low-level povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-level povidone-iodine preparations (0.5-20 ppm free iodine)
Trial: 7738344
Drug: Commercial povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial povidone-iodine preparation
Trial: 2262896
Drug: Caffeine withdrawal
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine withdrawal (100 mg/day)
Trial: 30888265
Drug: Flocculent disinfection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flocculent disinfection (Procter and Gamble Purifier of Water [P&G PoW])
Trial: 30888265
Drug: Standard SAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SAM treatment protocol
Trial: 24433223
Drug: diclofenac+heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac+heparin
Trial: 16931507
Drug: Pramipexole 0.25
RxNorm normalized name: pramipexole 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25 mg/day
Trial: 16931507
Drug: Pramipexole 0.75
RxNorm normalized name: pramipexole 0.75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.75 mg/day
Trial: 21063131
Drug: Pramipexole 0.25
RxNorm normalized name: pramipexole 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25 mg/day (week 2)
Trial: 17322624
Drug: Flecainide 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 25 mg BID
Trial: 17322624
Drug: Flecainide 50
RxNorm normalized name: flecainide 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 50 mg BID
Trial: 17322624
Drug: Flecainide 100
RxNorm normalized name: flecainide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide 100 mg BID
Trial: 10563031
Drug: Methadone (33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (33% increase in daily dosage)
Trial: 9832970
Drug: Zolpidem (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (5, 10, and 20 mg/70 kg)
Trial: 8690830
Drug: Triazolam (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.125, 0.25, and 0.50 mg/70 kg)
Trial: 8690830
Drug: Temazepam (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (15, 30, and 60 mg/70 kg)
Trial: 27629730
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atorvastatin + 10 mg ezetimibe therapy for 6 months
Trial: 27629730
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin for 6 months
Trial: 21933330
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and lifestyle intervention (low glycaemic index diet and exercise programme)
Trial: 7611266
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron dextran (100 mg twice weekly)
Trial: 30683146
Drug: 1% simvastatin-acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% simvastatin-acid sodium salt ointment
Trial: 30683146
Drug: 1% atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% atorvastatin calcium salt ointment
Trial: 28454798
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 to 320 mg daily
Trial: 26054142
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Zhuang medicine at Qineihuan point and conventional acupuncture
Trial: 24060346
Drug: L‐NMMA (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (an unspecific nitric oxide synthase inhibitor)
Trial: 24060346
Drug: Phenylephrine (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (an α‐adrenoceptor agonist)
Trial: 20878646
Drug: Adjuvant treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatments
Trial: 19684412
Drug: Rigorous volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigorous volume management during thrice-weekly hemodialysis
Trial: 17412579
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (1500 mg/day)
Trial: 7946367
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Trial: 7946367
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) fentanyl (loading dose 1.5 micrograms/kg, infusion rate 1 micrograms/kg/hr)
Trial: 7946367
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (75 micrograms/hr)
Trial: 7946367
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) fentanyl
Trial: 3499244
Drug: Propofol (PROP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (PROP), 2.5 mg . kg‐1
Trial: 3499244
Drug: Thiopentone (THIO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (THIO), 4 mg . kg‐1
Trial: 3499244
Drug: Methohexitone (METH),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone (METH), 1.5 mg . kg‐1
Trial: 28905874
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine transdermal patch (TNP)
Trial: 28905874
Drug: Placebo transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch (PBO)
Trial: 16818281
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further donor cell infusion (group A)
Trial: 12621795
Drug: Recombinant follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant follicle-stimulating hormone (rFSH) 100 IU
Trial: 12621795
Drug: Urinary follicle-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary follicle-stimulating hormone (uFSH) 150 IU
Trial: 2679204
Drug: Traditional mixed-sex
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional mixed-sex alcoholism treatment centers
Trial: 29378998
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment applied to extraction sockets of the left third molars)
Trial: 21205136
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon (PEG‐IFN) plus low doses of ribavirin (800 mg/day) for 24 weeks
Trial: 21205136
Drug: shorter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shorter treatment (12‐16 weeks)
Trial: 21205136
Drug: shorter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: shorter treatment (12‐16 weeks) in subgroup with RVR
Trial: 21205136
Drug: prolonging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prolonging therapy
Trial: 17586189
Drug: Separate vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate vaccines
Trial: 17586189
Drug: DTaP-HepB-IPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-HepB-IPV plus Hib with PCV-7 administered 2 weeks later
Trial: 15473622
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (BM) - hyperbaric bupivacaine 0.5% 2 mL + 1 mL of 2mg preservative‐free midazolam
Trial: 15473622
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (B) - hyperbaric bupivacaine 0.5% 2 mL + saline 0.9% 1 mL
Trial: 11303198
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronized 17 beta‐estradiol daily sequentially combined with 5 or 10 mg dydrogesterone for 14 days of each 28‐day cycle during 12 months and thereafter 2 mg 17 beta‐estradiol combined with 10 mg dydrogesterone for a period of 3 months
Trial: 9627593
Drug: Milk formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk formula (MF; 67 cal/100 ml)
Trial: 28569520
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) focused on early change
Trial: 25908506
Drug: Weight-loss intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-loss intervention + 2000 IU/day oral vitamin D3
Trial: 25908506
Drug: Weight-loss intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-loss intervention + daily placebo
Trial: 22682669
Drug: Chemotherapy-first strategy
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-first strategy
Trial: 16678648
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 30 mg/d
Trial: 16678648
Drug: MAS XR
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS XR 40 mg/d
Trial: 9416933
Drug: Extended-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release isosorbide mononitrate (ER-ISMN) 60 mg
Trial: 9416933
Drug: Extended-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release isosorbide mononitrate (ER-ISMN) 120 mg
Trial: 8279667
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration (exact dosage not specified)
Trial: 8279667
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no alcohol, exact dosage not specified)
Trial: 3300945
Drug: Peptichemio (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptichemio (1.2 mg/kg/d) for two 5-day courses; Group 2
Trial: 3300945
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further antitumor therapy; Group 1
Trial: 28586623
Drug: Follow-up survey
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up survey measuring vaccine hesitancy scores
Trial: 28586623
Drug: Follow-up survey
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up survey measuring the proportion of vaccine hesitant mothers
Trial: 19577829
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received the same care without reflexology therapy)
Trial: 7988251
Drug: Immediate combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate combination chemotherapy (CAP)
Trial: 7988251
Drug: Delayed combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed combination chemotherapy (CAP)
Trial: 2729939
Drug: Oral antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antacid (30 ml of aluminum hydroxide orally four times a day for 4 days)
Trial: 30442233
Drug: Diet/Ca/D (cholecalciferol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet/Ca/D (cholecalciferol 50,000 IU/subject/week and calcium 1200 mg/dL/subject/day)
Trial: 30442233
Drug: Diet/Ca (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet/Ca (calcium 1200 mg/dL/subject/day)
Trial: 30442233
Drug: CON (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (no prescribed supplements)
Trial: 24648723
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/day, n=25)
Trial: 24648723
Drug: No fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fluoxetine (control group, n=25)
Trial: 22198621
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea infusate (3 x 200 ml/day for 12 weeks)
Trial: 20515467
Drug: Intravenous rehydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rehydration (IVR)
Trial: 16146476
Drug: diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac 50 mg x 3
Trial: 10393606
Drug: Beclomethasone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone therapy
Trial: 8930940
Drug: PD (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD (120 mg orally)
Trial: 2034826
Drug: Isovolemic hemodilution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isovolemic hemodilution (15 ml/kg body weight) with lumbar epidural anesthesia
Trial: 24501384
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (LGG), once daily for 4 weeks
Trial: 21963389
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (2×100 ml/d for 8 weeks)
Trial: 21963389
Drug: Placebo (2×100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2×100 ml/d for 8 weeks)
Trial: 29631782
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg oral daily)
Trial: 11960396
Drug: All trans
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All trans retinoic acid (ATRA) 45 mg/m²/day from day 1 to complete remission combined with Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days.
Trial: 11960396
Drug: Idarubicin 10
RxNorm normalized name: IDArubicin 10 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin 10 mg/m²/day for 3 days and cytarabine 1000 mg/m²/12 h for 6 days without ATRA.
Trial: 11960396
Drug: ATRA combined
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA combined with chemotherapy (Idarubicin and Cytarabine).
Trial: 10190855
Drug: CD pedicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD pedicle screw implants
Trial: 7577781
Drug: Blind standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind standard technique (group A: 8 mL bupivacaine 0.25%)
Trial: 7577781
Drug: Ultrasonographic imaging
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonographic imaging technique (group B: 5 mL bupivacaine 0.25%)
Trial: 2034479
Drug: HiFe (13.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HiFe (13.8 mg elemental iron)
Trial: 2034479
Drug: MidFe (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MidFe (7 mg elemental iron)
Trial: 7326166
Drug: L(+) mepivacaine
RxNorm normalized name: L-(-)-bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L(+) mepivacaine
Trial: 7326166
Drug: L(+) and
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L(+) and D(‐) mepivacaine
Trial: 23557627
Drug: Hydrocortisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (20 mg bid for 10 days)
Trial: 20499072
Drug: Calorie‐restricted legume‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie‐restricted legume‐based diet (L‐diet)
Trial: 18282237
Drug: Community-wide azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Community-wide azithromycin treatment
Trial: 16531164
Drug: Monophasic OC
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic OC containing 35 mug EE and 2 mg cyproterone acetate (CPA; n=10)
Trial: 10895744
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine with fentanyl 1 microgram ml‐1
Trial: 10895744
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine with fentanyl 2 micrograms ml‐1
Trial: 10895744
Drug: Low-concentration/high-volume solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-concentration/high-volume solution
Trial: 9561637
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation for 12 weeks
Trial: 9561637
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation for 12 weeks
Trial: 1532940
Drug: Domiciliary nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domiciliary nebulized fenoterol (F) 1.25 mg and ipratropium (I) 0.5 mg for three weeks
Trial: 3157576
Drug: Zimeldine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimeldine (200 mg/day, increased to 300 mg/day after 7 days)
Trial: 18407382
Drug: AS‐H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐H5N1 vaccine
Trial: 18407382
Drug: Fluarix (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluarix (licensed seasonal influenza vaccine)
Trial: 15206667
Drug: Olanzapine at
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine at >16 mg
Trial: 15206667
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at 4 mg
Trial: 15206667
Drug: Ziprasidone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone at 120 mg
Trial: 15206667
Drug: Risperidone at
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone at 2 mg daily
Trial: 15206667
Drug: Olanzapine at
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine at 6 mg